Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?

The future of GVHD management is shifting from broad immunosuppression toward precision medicine. We anticipate a transition from the current 'steroid-first' paradigm to risk-stratified algorithms utilizing biomarker profiling and novel combination strategies. While ruxolitinib is the current cornerstone, the development of highly selective inhibitors and the resolution of financial access barriers will be crucial for establishing JAK inhibitors as the frontline standard of care over the next decade.